- 作者：Marta Ram¨ªrez Lapausa ; Jos¨¦ Francisco Pascual Pareja ; Arturo Noguerado Asensio
- 关键词：Tuberculosis multirresistente ; Nuevos fá ; rmacos ; Fluoroquinolonas ; Nitroimidazoles ; Diarilquinolina ; Oxazolidinona ; SQ109
- 刊名：Medicina Clnica
- 出版年：2013
- 出版时间：5 October, 2013
- 年：2013
- 卷：141
- 期：7
- 页码：306-313
- 全文大小：408 K
Drug-resistant tuberculosis is a globally emerging problem with a rising incidence. According to the WHO in 2008, 17 % of strains of Mycobacterium tuberculosis, in untreated cases were resistant to at least one drug and 3.6 % were resistant to rifampicin and isoniazid, which is called multidrug-resistant tuberculosis. The problem is greater in patients previously treated and in some countries, where rates of multidrug resistance reach 60 % . Approximately 5 % of multidrug-resistant tuberculosis patients are also resistant to any fluoroquinolone and at least one injectable drug, being called extensively drug-resistant tuberculosis. The treatment of these forms of tuberculosis requires the use of second-line drugs, which causes higher cost, higher toxicity and a longer duration of treatment. There is a need for new compounds with efficacy and safety profiles better than those currently used to treat these forms of tuberculosis. In the last decade different drugs have being reassessed and appeared, which are at different stages of development.